Functionality of Endogenous Biological Clock in Sepsis

December 10, 2023 updated by: Evangelos J. Giamarellos-Bourboulis, M.D., University of Athens
The aim of the current study is to demonstrate dysregulation of immune system΄s circadian rhythms as a consequence of sepsis, as well as marked malfunction of the central circadian clock in comparison with patients without sepsis , the presence of which burdens independently the final outcome and , hence, need to be addressed.

Study Overview

Status

Recruiting

Detailed Description

Sepsis is number one cause of death within the critically ill patients ,with mortality that reaches a rate of 70%,while in case of the establishment of septic shock and multi organ failure it can rise up to 80%.Septic shock is the most common cause of death in the ICUs. It has been estimated that 25% of the total of septic patients will develop severe sepsis (sepsis and organ failure), while septic shock (sepsis and cardiovascular failure).

In order to call a biological rhythm circadian, the following 3 criteria must be satisfied:

  1. Insistence on stable conditions, with endogenous period of about 24 hours.
  2. Independence of ambient temperature, so that almost always progresses at the same rate (same frequency), independent of temperature.
  3. This endogenous rhythm, of approximately 24 hours, can be synchronized in exactly 24 hours, influenced by environmental factors, such as light/dark cycles, social interactions, etc.

Many organic systems follow a circadian pattern, among others the immune system,on the grounds that peripheral blood lymphocytes own all the forementioned genes, whose coordinated expression with that particular periodicity results in the generation of maximum (peak) and minimum (nadir) of the number of circulating cells, their activity, the production and secretion of cytokines etc.This endogenous attitude is lost in case of sepsis, due to few or absent stimuli deriving from the central clock. As a result, an additional compounding factor comes up in the immune system ,which fails to fight the infectious agent and that inefficient immune response aggravates the circadian desynchronization , creating a vicious circle.

The direct evaluation of circadian rhythms' entails the examination of suprachiasmatic neurons' functionality, through biopsies from the examined patients ,which constitutes an ethically questionable ,practically expensive, time-consuming and quite demanding procedure. Thus, the estimation of actual circadian profile will take place indirectly, driven by a series of biomarkers, indicative of the functional status of the ''central biological clock'' found at the suprachiasmatic nucleus of CNS (melatonin, cortisol, core body temperature),as well as the ''peripheral clock'' placed at the immune system cells (Clock/ Bmal1 , Per/Cry genes' expression).

The purpose of this prospective, observational, case-control study is to investigate the discrepancy in levels of circadian biomarkers in patients suffering from sepsis in comparison with those coming from other ,non-septic patients in the same environment as well as deviation from healthy controls' values, and secondarily to assess the effect of septic syndrome in later development of endogenous clock that regulates daily life with regard to the quality of life that follows recovery.

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Evangelos J Giamarellos-Bourboulis, MD, PhD
  • Phone Number: +302107480662
  • Email: egiamarel@med.uoa.gr

Study Contact Backup

Study Locations

    • Attiki
      • Athens, Attiki, Greece, 12462
        • Recruiting
        • 4th Department of Internal Medicine, Attikon University Hospital
        • Contact:
          • Evangelos J Giamarellos-Bourboulis, MD, PhD
          • Phone Number: +302107480662
          • Email: egiamarel@med.uoa.gr
        • Contact:
          • Maria G Kalogridi, MD
          • Phone Number: +302105831916
      • Athens, Attiki, Greece, 12462
        • Recruiting
        • 2nd Department of Intensive Care Medicine, Attikon University Hospital
        • Contact:
          • Apostolos Armaganidis, MD, PhD
          • Phone Number: 0030 210 5832183
          • Email: aarmag@med.uoa.gr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

  • GROUP A: absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
  • GROUP Β: control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
  • GROUP C: patients with sepsis as defined by the Sepsis-3 classification criteria3

Description

Inclusion Criteria:

  • Adults (age ≥18 years)
  • Written informed consent
  • Male or female gender
  • Οne of the following cases:

    • Healthy controls without comorbidities OR
    • Patients without sepsis or infection , with identical Charlson Comorbidity Index and same mental status with the septic patients OR
    • Patients with sepsis

Exclusion Criteria:

  • Failure to obtain written informed consent
  • Age <18 years
  • Pregnancy or breastfeeding
  • Solid tumor or hematologic malignancy
  • Asthma
  • Neurodegenerative disease
  • Traumatic brain injury
  • Confirmed depression
  • Autoimmune disorders
  • Special categories following unfixed or varying routine schedules (e.g. travels overseas or even short distances, if frequent/jet lag/on-call duties/nightshifts with regard to doctors,security guards,singers)
  • Per os or iv corticosteroids daily intake of dose at least
  • Corticosteroid oral or intravenous intake of at least 0.4 mg/kg of equivalent prednisone daily over the last 15 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
GROUP A
Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
GROUP B
Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
GROUP C
Patients with sepsis as defined by the Sepsis-3 classification criteria3

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The substantial discrepancy in the values of melatonin, cortisol and core body temperature (central CLOCK circadian markers) between septic and non-septic patients.
Time Frame: 7 days
Different values in melatonin,cortisol, core body temperature .
7 days
The substantial discrepancy in the circadian rhythms' genes expression levels (peripheral clock markers) between septic and non-septic patients ,within their peripheral blood leucocytes .
Time Frame: 7 days
Different mRNA levels of clock, bmal1, per, cry genes within peripheral blood leucocytes.
7 days
The difference in the extent of deviation from normal, with regard to the values of melatonin-cortisol-core body temperature (circadian triad) between septic and non-septic patients.
Time Frame: 7 days
Extent of abnormality in the values of melatonin,cortisol and core body temperature .
7 days
The difference in the extent of deviation from normal, with regard to the levels of circadian rhythms' genes expression (immune system's clock) between septic and non-septic patients ,within their peripheral blood leucocytes .
Time Frame: 7 days
Extent of abnormality in the mRNA levels of clock, bmal1, per, cry genes within peripheral blood leucocytes.
7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality rate at 28 days.
Time Frame: 28 days
Differences in early (28-day) all-cause mortality rate between septic and matched non-septic patients .
28 days
Mortality rate at 90 days.
Time Frame: 90 days
Differences in middle term (90-day) all-cause mortality rate between septic and matched non-septic patients.
90 days
Munich ChronoType Questionnaire results ,including Mid-sleep, Sleep Duration on both work and free days (MSw, MSf, MSfsc, SLDw, SLDf, SLDØ, chronotype).
Time Frame: 30 days
Rate of circadian physiology restoration, concerning the discharged subgroup which is recovering from sepsis, with regard to daily routine and quality of life.
30 days
Pittsburgh Sleep Quality Index (Global PSQI Score).
Time Frame: 30 days
Sum (range 0 to 21) of seven components,each scored 0 (no difficulty) to 3 (severe difficulty).These entail Subjective sleep quality, Sleep latency, duration, efficiency and disturbance, in addition to Use of sleep medication and Daytime dysfunction.
30 days
Munich ChronoType Questionnaire results ,including Mid-sleep, Sleep Duration on both work and free days (MSw, MSf, MSfsc, SLDw, SLDf, SLDØ, chronotype).
Time Frame: 60 days
Rate of circadian physiology restoration ,concerning the discharged subgroup which is recovering from sepsis, with regard to daily routine and quality of life.
60 days
Pittsburgh Sleep Quality Index (Global PSQI Score).
Time Frame: 60 days
Sum (range 0 to 21) of seven components,each scored 0 (no difficulty) to 3 (severe difficulty).These entail Subjective sleep quality, Sleep latency, duration, efficiency and disturbance, in addition to Use of sleep medication and Daytime dysfunction.
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Evangelos J Giamarellos-Bourboulis, MD, PhD, University of Athens

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 3, 2019

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

August 13, 2019

First Submitted That Met QC Criteria

August 17, 2019

First Posted (Actual)

August 21, 2019

Study Record Updates

Last Update Posted (Actual)

December 12, 2023

Last Update Submitted That Met QC Criteria

December 10, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

3
Subscribe